You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Further clinical evidence of intractable Chronic Cluster Headache (iCCH) patients receiving Occipital Nerve Stimulation (ONS) therapy has been released, confirming that ONS is a promising treatment that may reduce attacks frequency and intensity on these suffering patients1.
had ≥ 50% reduction in CH Frequency1
had ≥ 30% reduction in CH Frequency1
would recommend ONS to other patients1
The AnkerStimTM lead is designed to resist migration and improve comfort.
AnkerStim™ was developed on the initiative of Prof. Jean-Pierre Van Buyten and Dr. Iris Smet. Listen to their thoughts regarding ONS, Cluster Headache and AnkerStimTM, and watch them guide us through an implant procedure.
Occipital Nerve Stimulation Using the AnkerStim Lead - (10:50)
This segment is not intended to be used in place of the IFUs. Please consult product manuals for complete information.
More information (see more) Less information (see less)
'For Implantable Pain Stimulation devices in Western Europe (status: June 2021) ‘
Wilbrink LA, de Coo IF, Doesborg PGG, Mulleners WM, Teernstra OPM, Bartels EC, Burger K, Wille F, van Dongen RTM, Kurt E, Spincemaille GH, Haan J, van Zwet EW, Huygen FJPM, Ferrari MD, for the ICON study group. Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurol 2021; 20: 515–25.